Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Panbela Therapeutics Inc (PBLA)

Panbela Therapeutics Inc (PBLA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.3432 +0.0219 (+6.82%) 04/22/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.3432 unch (unch) 15:45 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.2800
Day High
0.3432
Open 0.2937
Previous Close 0.3213 0.3213
Volume 3,000 3,000
Avg Vol 16,725 16,725
Stochastic %K 64.00% 64.00%
Weighted Alpha -31.40 -31.40
5-Day Change +0.0392 (+12.89%) +0.0392 (+12.89%)
52-Week Range 0.2650 - 0.4998 0.2650 - 0.4998
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 1,560
  • Shares Outstanding, K 4,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,260 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -71.13
  • Most Recent Earnings $-1.48 on 11/14/24
  • Next Earnings Date 05/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -65.90
  • Growth Rate Est. (year over year) +1,615.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2650 +29.51%
on 04/16/25
Period Open: 0.3330
0.3514 -2.33%
on 03/28/25
+0.0102 (+3.06%)
since 03/21/25
3-Month
0.2650 +29.51%
on 04/16/25
Period Open: 0.4021
0.4729 -27.43%
on 02/26/25
-0.0589 (-14.65%)
since 01/22/25
52-Week
0.2650 +29.51%
on 04/16/25
Period Open: 0.4748
0.4998 -31.33%
on 05/15/24
-0.1316 (-27.72%)
since 04/22/24

Most Recent Stories

More News
Panbela Provides Business Update and Reports Q3 2024 Financial Results

PBLA : 0.3432 (+6.82%)
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

PBLA : 0.3432 (+6.82%)
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Expects interim data by early 2024...

PBLA : 0.3432 (+6.82%)
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 0.3432 (+6.82%)
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 0.3432 (+6.82%)
PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA

Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed transaction,...

PBLA : 0.3432 (+6.82%)
Panbela to Host Virtual R&D Day

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3432 (+6.82%)
Panbela Announces Poster Presentation at American Association for Cancer Research:

The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer...

PBLA : 0.3432 (+6.82%)
PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to...

PBLA : 0.3432 (+6.82%)
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

PBLA : 0.3432 (+6.82%)
Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET

MINNEAPOLIS, March 23, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3432 (+6.82%)
Panbela to Participate in the 34th Annual Roth Conference

MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3432 (+6.82%)
Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results

MINNEAPOLIS, March 08, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3432 (+6.82%)
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

MINNEAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3432 (+6.82%)
PANBELA THERAPEUTICS INVESTOR ALERT By The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to...

PBLA : 0.3432 (+6.82%)
PBLA Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Panbela Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Panbela Therapeutics, Inc. (NASDAQ: PBLA) and Cancer Prevention Pharmaceuticals, Inc. is fair to Panbela shareholders....

PBLA : 0.3432 (+6.82%)
Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3432 (+6.82%)
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting

Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than...

PBLA : 0.3432 (+6.82%)
Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines; Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022

Company to host a virtual R&D day to discuss the new ovarian cancer program in the new year...

PBLA : 0.3432 (+6.82%)
Panbela Provides Business Update and Reports Q3 2021 Financial Results

MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.3432 (+6.82%)

Business Summary

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma,...

See More

Key Turning Points

3rd Resistance Point 0.4275
2nd Resistance Point 0.3853
1st Resistance Point 0.3643
Last Price 0.3432
1st Support Level 0.3011
2nd Support Level 0.2589
3rd Support Level 0.2379

See More

52-Week High 0.4998
Fibonacci 61.8% 0.4101
Fibonacci 50% 0.3824
Fibonacci 38.2% 0.3547
Last Price 0.3432
52-Week Low 0.2650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.